Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices ranging from HK$27.20 to HK$28.00, translating to a volume-weighted average cost of HK$27.63 per share and a total consideration of HK$0.77 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02% to 135.21 million shares, while treasury shares rose to 1.01 million. Total issued shares, including treasury stock, remained unchanged at 136.22 million.

The repurchase was executed under the mandate approved on 12 February 2026, which authorises buybacks of up to 13.62 million shares. Cumulatively, HANXBIO-B has repurchased 1.01 million shares under this mandate, equivalent to 0.74% of the issued share count at the mandate date.

In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 July 2026. The board confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.